Brought to you by 
Genentech licenses NovImmune's NI1401
10 Apr 2020
Executive Summary
Roche's Genentech Inc. has licensed exclusive rights to NovImmune SA's (MAbs for inflammation and immune disorders) NI1401, an anti-IL-17 fully human MAb, as well as access to back-up antibodies.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genentech licenses NovImmune's NI1401
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice